Shire commits up to $535M for Parion's dry eye drug

Looking to expand its ophthalmic offerings, the Irish pharma announced it is adding a new mid-stage candidate to its pipeline.

By Jacob Bell • May 1, 2017

Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan

Tuesday is expected to be another busy days for earnings reports, with Pfizer and big biotechs like Gilead announcing financial performance for the first quarter. 

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • May 1, 2017

Prescribed Reading: Rough start for pharma, but optimism abounds

First quarter earnings were not particularly strong, but there were several bright spots; Gottlieb confirmation rolls forward; and The Medicines Co. lays down cash for its CV outcomes trial.

By Lisa LaMotta • April 28, 2017

Amgen, Novartis tweak partnership on migraine drug

The companies are readying a regulatory submission for erenumab, one of several CGRP inhibitors nearing the market for prevention of migraine. 

By Suzanne Elvidge • April 26, 2017

Capitalize on your merger/acquisition: 4 tips to consolidate your CMO network

Establish measurable objectives, set criteria for CMO evaluation, outline geographic requirements, and rationalize your portfolio to improve outcomes in network consolidation.

April 25, 2017

Fresenius Kabi picks up generic maker Akorn for $4.3B

A deal between the German company's U.S. subsidiary and the specialty generic drugmaker is a logical fit, analysts say. 

By Lisa LaMotta • April 25, 2017

Prescribed Reading: What J&J says about the rest of pharma

J&J earnings predict a rough first quarter for big pharma, AbbVie has a bad week, and Lilly's surprise rejection is great news for Pfizer. 

By Lisa LaMotta • April 21, 2017

Former Dendreon CEO debuts new public company in reverse merger

Alpine Immune Sciences will merge with a subsidiary of Nivalis Therapeutics, which had been searching for a way forward after a clinical failure. 

By Ned Pagliarulo • April 19, 2017

Allergan, Novartis ink NASH partnership

The deal will pair Allergan's drug cenicriviroc and Novartis' candidate LJN452 in a Phase 2b study of patients with the liver disease.

By Jacob Bell • April 18, 2017

Amarantus creates spinouts in restructuring

The biotech is keeping its eye on the future with spinouts in ophthalmology and CNS disorders.

By Suzanne Elvidge • April 18, 2017

Bristol-Myers taps Danish biotech in NASH biomarker deal

The partnership with Nordic Bioscience reflects the challenges of accurately diagnosing NASH, sometimes termed a "silent" disease. 

By Ned Pagliarulo • April 17, 2017

Biogen, Roche ink deals with Bristol for rare disease drugs

Biogen is licensing a potential Alzheimer's treatment, Roche is getting rights to a DMD drug and Bristol-Myers Squibb is pocketing money for other projects.

By Jacob Bell • April 13, 2017

Biopharma IPOs sluggish in Q1. Will that continue?

With venture funding leveling off and just four IPOs in the first quarter, industry followers aren't expecting a record-breaking year for private biopharma exits.

By Jacob Bell • April 13, 2017

Could organs on a microchip help test for toxins? The FDA wants to find out

The regulator will collaborate with the private Emulate, Inc. to test the company's organ-on-a-chip technology as a potential toxicology testing platform.

By Suzanne Elvidge • April 13, 2017

SV Health secures $400M for new life sciences venture fund

Although biotech IPO activity remains weak, investors are still showing a willingness to pour fresh money into early-stage companies. 

By Ned Pagliarulo • April 12, 2017

Stada backs $5.6 billion takeover offer from Bain, Cinven

The German generics maker has been under pressure from an activist investor to overhaul its governance structure. 

By Suzanne Elvidge • April 11, 2017

J&J taps peptide technology in $1.15B discovery deal

Tokyo-based PeptiDream stock jumped 19% after the company scored a discovery-stage deal with Johnson & Johnson. 

By Suzanne Elvidge • April 10, 2017

OncoMed slammed by fizzled Bayer deal, Phase 2 failure

The cancer-focused company saw shares slide nearly 43% in premarket trading on Monday.

By Jacob Bell • April 10, 2017

Generics maker Akorn jumps on Fresenius takeout talks

After rumors swirl, Fresenius Kabi and Akorn confirm that they are in acquisition talks.

By Suzanne Elvidge • April 10, 2017

Prescribed Reading: AACR, Gottlieb and recalls

Scott Gottlieb faced a Senate committee for the top slot at the FDA, while data pours in from AACR and Mylan and GSK issue U.S. recalls.

By Lisa LaMotta • April 7, 2017

Novartis licenses bite-sized biotech's dry eye drug

The deal with Lubris Biotech adds another candidate to Novartis ophthalmology pipeline, which may help the company's struggling eye care business down the line. 

By Jacob Bell • April 7, 2017

5 years on: Good policy helps biotech

The trade association BIO celebrates the accomplishments of the industry since the advent of the JOBS Act five years ago. 

By Lisa LaMotta • April 6, 2017

RedHill acquires rights to medical food from Entera Health

In exchange for tiered sales royalties, the specialty pharma now holds exclusive rights to EnteraGam, a product that helps regulate bowel movements.

By Jacob Bell • April 5, 2017

Sucampo bolsters pipeline with rare disease buy

The biotech agreed to pay $200 million upfront for privately-held Vtesse and its rare disease drugs. 

By Suzanne Elvidge • April 4, 2017

Astellas buys Ogeda in deal worth up to $850M

The transaction adds a mid-stage candidate for the treatment of menopause symptoms to the Japanese pharma's pipeline. 

By Jacob Bell • April 3, 2017